However, although we have demonstrated that NTBC block the binding of HPD to target mRNA in vivo and in vitro, NTBC, as a drug targeting the metabolic function of HPD, cannot accurately indicate whether its inhibitory effect on ovarian cancer is achieved by blocking the RBD function of HPD or by inhibiting the activity of metabolic enzymes. The gene discussed is HPD; the disease is ovarian carcinoma.